MR enhancement features of multistep hepatocarcinogenesis in HBV-related cirrhotic livers: correlation with GPC-3 and CD34

doi:10.3969/j.issn.1006-7795.2016.05.022

Abstract

Abstract: Objective To study the correlation between MR(magnetic resonance) enhancement features and GPC-3 (glypican-3) and CD34 expression in hepatic B Virus (HBV)-related liver cirrhosis nodules. Methods This retrospective study collected 47 pathology proven nodules in 44 HBV-related liver cirrhosis patients, who underwent MRI and made the time-signal curve of dynamic enhancement, and we also evaluated the immunohistochemical biomarkers levels of GPC-3 and CD34. Results 1) In the 47 nodules, GPC-3 positive rate in early hepatocellular carcinoma (eHCC), high grade dysplastic nodule (HGDN), low grade dysplastic nodule(LGDN) were 78.9%, 26.1% and 0%, respectively (P=0.000), CD34 positive rates were respectively 78.9%, 56.5%, 0%, and the difference was statistically significant (P=0.005). 2) The MR time-signal features at different stage of nodules, GPC-3 positive and negative nodules, CD34 strongly positive and weakly positive and negative nodules, were statistically significant(P<0.05). Conclusion 1) MR time-signal curve has a certain differential diagnostic value for early stage of HCC. 2) GPC-3 is a highly specific biomarker for the malignance, while MR time-signal curve inclined to show rapid rise type. 3) CD34 expression was positively correlated with MR time-signal curve.

Key words: liver cirrhosis, dysplastic nodules, early hepatocellular carcinoma, magnetic resonance imaging, GPC-3, CD34

CLC Number:

Zhang Qi, Li Hongjun, Li Yunfang, Zhang Yanyan, Yuan Xingxing, Chang Jing. MR enhancement features of multistep hepatocarcinogenesis in HBV-related cirrhotic livers: correlation with GPC-3 and CD34[J]. Journal of Capital Medical University, 2016, 37(5): 672-679.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.05.022

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I5/672

References

[1] Liu J,Fan D.Hepatitis B in china[J].Lancet,2007,369(9573):1582-1583.
[2] 李淑群, 陈谦. GP73与肝脏疾病关系的研究进展[J]. 世界华人消化杂志, 2010, 18(20):2117-2120.
[3] Yao M, Yao D F, Bian Y Z, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2011, 10(3):289-294.
[4] Huh J, Kim K W, Kim J, et al. Pathology-MRI Correlation of Hepatocarcinogenesis:Recent Update[J]. J Pathol Transl Med, 2015, 49(3):218-229.
[5] Nakamura K,Zen Y,Sato Y,et al. Vascular endothelial growth factor,its receptor FLK-1,and hypoxia inducible factor-lalpha are involved in malignant transformation in dysplastic nodules of the liver[J].Hum Pathol,2007,38(10):1532-1546.
[6] Coston W M,Loera S,Lan S K,et al.Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican 3 and CD34 immunohistochemistry[J].Am J Surg Pathol,2008,32(3):433-444.
[7] Enan E T, El-Hawary A K, EI-Tantawy D A, et al. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions[J]. Ann Diagn Pathol,2013,17(6):490-493.
[8] Saad R S, Luckasevic T M, Noga C M, et al. Diagnostic value of HepPar1, pCEA, CD10,and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology[J]. Diagn Cytopathol, 2004,30(1):1-6.
[9] Gong L, Wei L X, Ren P, et al.Dysplastic nodules with Glypican-3 immunostaining:A risk for early hepatocelluar carcinoma[J].PLOS One, 2014,9(1):e87120.
[10] Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules[J]. Am J Surg Pathol, 2006, 30(11):1405-1411.
[11] Wang X Y, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors:diagnostic value for preneoplastic lesions and hepatocellular carcinomas[J]. Human pathol, 2006, 37(11):1435-1441.
[12] Wang H L, Anatelli F, Zhai Q J, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions[J]. Arch Pathol Lab Med,2008, 132(11):1723-1728.
[13] Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma[J]. Mod Pathol,2005,18(12):1591-1598.
[14] 杜经丽, 韦立新, 王玉兰. 磷脂酰肌醇蛋白聚糖-3等抗体在高分化肝细胞肝癌中的表达及其鉴别诊断意义[J]. 中华病理学杂志, 2011, 40(1):11-16.
[15] Yao S, Zhang J, Chen H, et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma[J]. J Histochem Cytochem, 2013,61(9):639-648.
[16] 畅俊平, 王丽霞. GPC3和CD34在肝细胞性肝癌中的表达及临床意义[J]. 中国药物与临床, 2013, 13(z1):4-5.
[17] Kim H D, Lim Y S, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival[J]. Gastroenterology, 2015, 148(7):1371-1382.